Clinical Drug Experience Knowledgebase

cytarabine (cytosar-u) (3 trials)

idarubicin (idamycin) (1 trial)

mitoxantrone (novantrone) (1 trial)

tretinoin (Retin-A) (1 trial)

acalabrutinib (calquence) (2 trials)

ag-120 (1 trial)

allogeneic stem cells (1 trial)

anidulafungin (eraxis) (1 trial)

autologous bone marrow (1 trial)

autologous bone marrow derived mesenchymal cells (1 trial)

bendamustine (treanda) (1 trial)

bortezomib (velcade) (4 trials)

cyclophosphamide (cytoxan) (9 trials)

daratumumab (darzalex) (1 trial)

daunorubicin (cerubidine) (1 trial)

doxorubicin (Doxil) (3 trials)

enasidenib (idhifa) (1 trial)

fludarabine (fludara) (2 trials)

gemtuzumab ozogamicin (mylotarg) (1 trial)

gilteritinib (1 trial)

ibrutinib (imbruvica) (4 trials)

interferon alpha-2b (Intron-A) (2 trials)

lenalidomide (revlimid) (2 trials)

melphalan (alkeran) (2 trials)

midostaurin (rydapt) (2 trials)

obinutuzumab (gazyva) (3 trials)

peripheral blood hematopoietic cell (1 trial)

prednisone (meticorten) (6 trials)

rituximab (rituxan) (6 trials)

sargramostim (leukine) (1 trial)

thalidomide (Thalomid) (1 trial)

urea (7 trials)

venetoclax (venclexta) (7 trials)

vincristine (oncovin) (4 trials)

voriconazole (vfend) (1 trial)

ari-0001 (1 trial)

atezolizumab (tecentriq) (2 trials)

axi-cel (1 trial)

blinatumomab (blincyto) (1 trial)

brentuximab vedotin (adcetris) (1 trial)

carfilzomib (kyprolis) (6 trials)

cisplatin (platinol) (1 trial)

decitabine (dacogen) (1 trial)

dexamethasone (2 trials)

etoposide (vepesid) (1 trial)

Flotetuzumab (1 trial)

gemcitabine (gemzar) (1 trial)

nivolumab (opdivo) (1 trial)

pacritinib (Vonjo) (1 trial)

pomalidomide (pomalyst) (1 trial)

tislelizumab (1 trial)